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and more rapid eGFR increases post-switch amongst those exposed
to TDF, compared to those unexposed. Further, there was no
significant difference in pre- and post-switch eGFR slopes amongst
those not receiving TDF. Significant changes in eGFR slopes were still
observed following switch to DRV in those who did not also
discontinue TDF at the time of the switch (Table 1).
Conclusions: Improved kidney function was observed in patients
who switched from ATV or LPV to DRV, particularly amongst those
with renal dysfunction and those exposed to TDF prior to switching,
suggesting that DRV may have a more favourable renal safety profile.
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Introduction: Tenofovir is recommended for the antiretroviral
treatment of HIV-positive adults in Sub-Saharan Africa, including
individuals co-infected with HBV. Use of TDF is gradually expanding in
the region, where evidence indicates a high burden of pre-existing
renal disease. This cross-sectional analysis evaluated the renal profile
of HIV/HBV co-infected subjects receiving long-term TDF as part of
ART in Kumasi, Ghana.
Methods: Patients underwent a comprehensive clinical and labora-
tory assessment, including serum biochemistry with creatinine and
eGFR (CKD-EPI), urinary protein-to-creatinine ratio (uPCR), albumin-
to-protein ratio (uAPR; if uPCR 520 mg/mmol), glycated haemoglo-
bin (HbA1c), urinary schistosoma antigen, full blood count and CD4
cell count, and HIV-1 RNA and HBV DNA load. Tubular proteinuria
(TP) was defined as a uPCR 20 mg/mmol in the absence of
significance albuminuria (uAPR B0.4 mg/mmol).
Results: The study comprised 101 subjects (66% women; mean age
45 years) that had received ART for median 7.9 years (IQR 6.09.2)
and TDF for median 4.1 years (3.94.3), 90% were on efavirenz
(n87) or nevirapine (n4) and 10% were on lopinavir/ritonavir
(LPV/r). CD4 counts were median 572 (383716) cells/mm3. Overall
21% had detectable HIV-1 RNA (40 copies/mL), with median levels
of 4.2 (2.15.1) log10 copies/mL; 17% had detectable HBV DNA
(15 IU/mL), with median levels of 2.4 (1.73.4) log10 IU/mL.
Blood pressure was raised in 35% of subjects and 10% had grade 3
elevations; 6% had diabetes (HbA1c ]48 mmol/mol and/or specific
treatment); 17% had a positive schistosoma test. Median uPCR was
13 (1320) mg/mmol; 28% had uPCR ]20 and 13% 50 mg/mmol.
TP was detected in 16% of participants and was independently
predicted by female gender (adjOR 10.5; 95% CI 1.388; p0.03)
and hypertension (adjOR 2.1 per grade increment; 95% CI 1.33.5;
pB0.01). Five of 13 patients with uPCR 50 mg/mmol had
uAPR B0.4, and this was associated with diabetes (OR 27; 95% CI
2.81265; pB0.01). Median eGFR was 103 (91115) and B60 mL/
min/1.73 m2 in 4%. When comparing the eGFR measured after
1 year of TDF with the current one, the mean eGFR change was
2.6 mL/min/1.73 m2/year (SD94.3), and independently pre-
dicted by LPV/r use (p0.05) and a suppressed HBV DNA load
(p0.01).
Conclusions: Subjects on stable ART in Ghana have a substantial
prevalence of comorbidities that can impact on renal function.
The findings point to an urgent need to define ascertainment and
management strategies for renal health in these populations.
Abstract P218Table 1. Pre- and post-switch eGFR slopes amongst individuals who switch from either atazanavir or lopinavir to
darunavir
Mean change in eGFR per year (95% CI)
N Pre-switch Post-switch p
All switchers
Atazanavir 676 0.97 (1.35, 0.59) 1.06 (0.69, 1.44) B0.001
Lopinavir 1015 0.51 (0.90, 0.12) 0.43 (0.14, 0.71) B0.001
Rapid eGFR decline (5 mL/min/1.73 m2)
Atazanavir 49 14.74 (18.79, 10.69) 2.55 (0.50, 4.61) B0.001
Lopinavir 42 12.99 (15.68, 12.30) 0.63 (0.85, 2.11) B0.001
eGFR B60 mL/min/1.73 m2
Atazanavir 87 6.59 (8.69, 4.48) 2.68 (1.23, 4.13) B0.001
Lopinavir 66 2.77 (4.08, 1.46) 2.13 (0.28, 3.99) B0.001
Received TDF prior to switch
Atazanavir 478 1.08 (1.52, 0.64) 1.47 (1.01, 1.93) B0.001
Lopinavir 605 0.90 (1.09, 0.52) 0.48 (0.13, 0.82) B0.001
Did not receive TDF prior to switch
Atazanavir 198 0.27 (0.93, 0.40) 0.69 (0.04, 1.34) 0.051
Lopinavir 410 0.35 (0.87, 1.57) 0.55 (0.05, 1.05) 0.777
Did not discontinue TDF at the time of switch
Atazanavir 530 0.42 (0.86, 0.02) 0.38 (0.07, 0.69) 0.006
Lopinavir 901 0.44 (0.74, 0.14) 0.52 (0.27, 0.77) B0.001
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